Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedA Publications section was added to the study record, listing a Nat Commun article about the related pembrolizumab/DPX-Survivac/cyclophosphamide trial and noting that publications are automatically filled from PubMed (Revision: v3.5.4).SummaryDifference0.3%

- Check10 days agoChange DetectedThere are no textual changes listed for this page in the provided data.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page footer was updated from “Revision: v3.5.0” to “Revision: v3.5.3,” reflecting a new ClinicalTrials.gov site/record display revision without changing the study details.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded revision note for v3.4.3 and removed the previous v3.4.2 revision.SummaryDifference0.1%

- Check97 days agoChange DetectedFallopian tube cancer was added to the Conditions section. A new page revision tag shows Revision: v3.4.2 (replacing v3.4.1).SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.